EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers

Katty Zeven, Herlinde Dierick, Matthijs Sevenois, Henri Baudhuin, Laurent Navarro, Sonja Van den Block, Jelena Saliën, Karine Breckpot, Jessica Bridoux, Timo W M De Groof iD, Nick Devoogdt

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07205-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Katty Zeven und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Positron-Emission Tomography, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kom op tegen Kanker, Wetenschappelijk Fonds Willy Gepts, Strategic Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Positron emission tomography remains the most important medical imaging technique for noninvasive imaging. Advances in radiotracer design, particularly those based on antibody(-formats), have broadened diagnostic applications. While minibodies and nanobodies stand out among antibody-type radiotracers due to their unique characteristics and pharmacokinetics, a direct comparison between these formats remains unexplored. In this study, we generated a so-called minabody, a minibody-like protein consisting of a nanobody fused to a CH3 domain, and compared it with its nanobody counterpart in vitro and in vivo upon labeling with various PET radionuclides. METHODS: A previously developed human TIGIT-targeting nanobody was reformatted to a minabody format to allow head-to-head comparison of both formats. The minabody and nanobody formats were compared in vitro for binding, specificity and stability. The minabody and/or nanobody formats were labeled with copper-64, gallium-68 or fluor-18 for non-invasive imaging of human TIGIT-expressing tumors by PET/CT over time. RESULTS: The minabody format showed higher binding affinities compared to the nanobody format. Despite lower binding affinity, the nanobody format outperformed the minabody format as PET imaging tracer showing higher specificity and allowing imaging of human TIGIT expression from 1 to 48 h post-injection upon labeling with copper-64. In addition, copper-64 showed superior tumor uptake and contrast for nanobody imaging compared to gallium-68 and fluor-18. CONCLUSION: This study describes the first head-to-head comparison between the minibody and nanobody format for PET imaging. Our results underscore the importance of considering both targeting vector format and the radionuclide to achieve accurate and high-quality PET imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesPositron-Emission TomographyPositron Emission Tomography Computed TomographyHumansAnimalsMiceCopper RadioisotopesRadioactive TracersCell Line, TumorRadiopharmaceuticals

Stichwörter der Autor:innen

MinabodyMinibodiesNanobodiesNuclear imagingPET imaging

Substanzen

Single-Domain AntibodiesCopper RadioisotopesRadioactive TracersRadiopharmaceuticalsCopper-64

Autor:innen und Institutionen

  • Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
  • Nuclear Medicine Department, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Abscint NV, Liège, Belgium.
  • Precirix NV, Brussels, Belgium.
  • Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), UMR CNRS 6302, Université de Bourgogne, Dijon, France.
  • Translational Oncology Research Center (TORC), Laboratory for Molecular and Cellular Therapy (LMCT), Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

ORCID-Profile: Timo W M De Groof

Förderung

  • Kom op tegen Kanker
  • Wetenschappelijk Fonds Willy Gepts
  • Strategic Research Program
  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Zeven, K., Dierick, H., Sevenois, M., Baudhuin, H., Navarro, L., Van den Block, S., Saliën, J., Breckpot, K., Bridoux, J., De Groof, T. W. M., & Devoogdt, N. (2025). Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07205-2

Vancouver

Zeven K, Dierick H, Sevenois M, Baudhuin H, Navarro L, Van den Block S, et al. Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07205-2

BibTeX
@article{Zeven2025,
  author = {Zeven, Katty and Dierick, Herlinde and Sevenois, Matthijs and Baudhuin, Henri and Navarro, Laurent and Van den Block, Sonja and Saliën, Jelena and Breckpot, Karine and Bridoux, Jessica and De Groof, Timo W M and Devoogdt, Nick},
  title = {Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07205-2}
}
Kostenlos starten →